Conceding to the requests of a coalition of pharmaceutical companies, FDA said it will issue additional guidances this year to clarify its policies on the communication of off-label uses of marketed drugs and devices.
Specifically, the agency will be releasing a draft guidance that addresses requests involving healthcare economic information, as well as guidances on unsolicited requests, distributing scientific and medical information on unapproved new